

# **Middle East Respiratory Syndrome (MERS) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs**

<https://marketpublishers.com/r/MDBABC528BD4EN.html>

Date: October 2019

Pages: 70

Price: US\$ 1,699.00 (Single User License)

ID: MDBABC528BD4EN

## **Abstracts**

Middle East Respiratory Syndrome (MERS) Drug pipeline report- 2020 is an annual R&D review of Middle East Respiratory Syndrome (MERS) pipeline candidates. The report presents the current status of all major Middle East Respiratory Syndrome (MERS) therapeutic compounds. Detailed insights into Middle East Respiratory Syndrome (MERS) pipeline development, current status, companies, drug profiles and Middle East Respiratory Syndrome (MERS) preclinical and clinical trials are included.

2020 Middle East Respiratory Syndrome (MERS) Pipeline Market Insights  
Middle East Respiratory Syndrome (MERS) disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Middle East Respiratory Syndrome (MERS) therapies, pipeline by phase and others are included.

Middle East Respiratory Syndrome (MERS) pipeline Drug profiles-  
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Middle East Respiratory Syndrome (MERS) Therapeutic Drug candidates  
Both active and inactive Middle East Respiratory Syndrome (MERS) pipeline drug candidates are included in the report

Middle East Respiratory Syndrome (MERS) Clinical Trials and preclinical Studies

Middle East Respiratory Syndrome (MERS) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Middle East Respiratory Syndrome (MERS) pipeline market developments  
Middle East Respiratory Syndrome (MERS) Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Middle East Respiratory Syndrome (MERS) pipeline companies in active development  
The report analyzes Middle East Respiratory Syndrome (MERS) pipeline of the below companies-

Autoimmune Technologies LLC, Fabentech, Gilead Sciences Inc, Global BioLife Inc Ltd, Greffex Inc, Humabs BioMed SA, Inovio Pharmaceuticals Inc, Kineta Inc, NanoViricides Inc, Novavax, Inc, Organic Vaccines PLC, Phelix Therapeutics LLC, Planet Biotechnology Inc, Regeneron Pharmaceuticals Inc, Romark Laboratories LC, SAB Biotherapeutics Inc, Signia Therapeutics, Themis Bioscience GmbH, Vaccitech Ltd, Vaxine Pty Ltd, Vir Biotechnology Inc

## Report Coverage

### What to look out for in 2020

Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

### Pipeline Snapshot

Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

### Companies

21 Companies investing in Middle East Respiratory Syndrome (MERS) pipeline from discovery stage to pre-registration phase are included

### Drug profiles

Over 10 details of each Middle East Respiratory Syndrome (MERS) pipeline candidate are included

### Company Profiles

Business overview and contact details of all companies operating in the industry are provided

Market Developments

News, Developments and other recent industry developments are included

## Contents

### **1. MIDDLE EAST RESPIRATORY SYNDROME (MERS) PIPELINE MARKET INSIGHTS, 2020**

- 1.1 Middle East Respiratory Syndrome (MERS) Disease Overview
- 1.2 Middle East Respiratory Syndrome (MERS) Drug Pipeline Snapshot, 2020
  - 1.2.1 Middle East Respiratory Syndrome (MERS) Pipeline Drugs by Phase
  - 1.2.2 Middle East Respiratory Syndrome (MERS) Pipeline Drugs by Company
  - 1.2.3 Middle East Respiratory Syndrome (MERS) Pipeline Drugs by Mechanism of Action
  - 1.2.4 Middle East Respiratory Syndrome (MERS) Pipeline Drugs by Route of Administration

### **2. MIDDLE EAST RESPIRATORY SYNDROME (MERS) COMPANY WISE PIPELINE DETAILS**

Autoimmune Technologies LLC Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Fabentech Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Gilead Sciences Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Global BioLife Inc Ltd Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Greffex Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Humabs BioMed SA Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Inovio Pharmaceuticals Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

**Kineta Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs**

Company Profile

Drug Candidate Details

**NanoViricides Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs**

Company Profile

Drug Candidate Details

**Novavax, Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs**

Company Profile

Drug Candidate Details

**Organic Vaccines PLC Middle East Respiratory Syndrome (MERS) Pipeline Drugs**

Company Profile

Drug Candidate Details

**Phelix Therapeutics LLC Middle East Respiratory Syndrome (MERS) Pipeline Drugs**

Company Profile

Drug Candidate Details

**Planet Biotechnology Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs**

Company Profile

Drug Candidate Details

**Regeneron Pharmaceuticals Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs**

Company Profile

Drug Candidate Details

**Romark Laboratories LC Middle East Respiratory Syndrome (MERS) Pipeline Drugs**

Company Profile

Drug Candidate Details

**SAB Biotherapeutics Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs**

Company Profile

Drug Candidate Details

**Signia Therapeutics Middle East Respiratory Syndrome (MERS) Pipeline Drugs**

Company Profile

Drug Candidate Details

**Themis Bioscience GmbH Middle East Respiratory Syndrome (MERS) Pipeline Drugs**

Company Profile

Drug Candidate Details

**Vaccitech Ltd Middle East Respiratory Syndrome (MERS) Pipeline Drugs**

Company Profile

Drug Candidate Details

**Vaxine Pty Ltd Middle East Respiratory Syndrome (MERS) Pipeline Drugs**

Company Profile

Drug Candidate Details  
Vir Biotechnology Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs  
Company Profile  
Drug Candidate Details

### **3. MIDDLE EAST RESPIRATORY SYNDROME (MERS) DRUG PIPELINE PROFILES**

3.1 Discovery and Preclinical Drug Profiles  
3.2 Phase 1 Drug Profiles  
3.3 Phase 2 Drug Profiles  
3.4 Phase 3 Drug Profiles

### **4. MIDDLE EAST RESPIRATORY SYNDROME (MERS) PIPELINE NEWS AND DEVELOPMENTS**

### **5. APPENDIX**

5.1 Primary and Secondary Research Methodology  
5.2 Publisher Expertize  
5.3 Contacts

## I would like to order

Product name: Middle East Respiratory Syndrome (MERS) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

Product link: <https://marketpublishers.com/r/MDBABC528BD4EN.html>

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MDBABC528BD4EN.html>